ACXP
$5.60-1.03 (-15.54%)
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the po...
Recent News
Can Acurx Pharmaceuticals (ACXP) Climb 226.3% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Acurx Pharmaceuticals (ACXP) points to a 226.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is Acurx Pharmaceuticals (ACXP) Outperforming Other Medical Stocks This Year?
Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Apyx Medical (APYX) have performed compared to their sector so far this year.
BC-Most Active Stocks
Elong Power Holding Ltd. 79,546,080 0.0559
Acurx Pharmaceuticals (ACXP) Secures New US Patent for DNA Polymerase IIIC Inhibitors
Acurx Pharmaceuticals Inc. (NASDAQ:ACXP) is one of the best up and coming penny stocks to buy. On February 2, Acurx Pharmaceuticals announced that the United States Patent and Trademark Office granted a new patent, US 12,534,470, covering its DNA Polymerase IIIC inhibitors. This patent includes compositions-of-matter, methods of use, and pharmaceutical compositions, reinforcing the company’s […]
Loss-Making Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Expected To Breakeven In The Medium-Term
With the business potentially at an important milestone, we thought we'd take a closer look at Acurx Pharmaceuticals...